Relationships Between Inflammatory Parameters Derived From Complete Blood Count and Quantitative Flow Ratio in

Yanqing Xie1,2, Han Cen2,3, Li Wang1

  • 1Department of Cardiology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.

Angiology
|August 26, 2023
PubMed

Insights

Inflammatory markers like monocyte-to-lymphocyte ratio (MLR) and systemic immune-inflammation index (SII) are linked to reduced coronary flow in stable coronary artery disease (CAD) patients. These findings highlight potential biomarkers for assessing disease severity.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biomarkers

Background:

  • Stable coronary artery disease (CAD) management relies on assessing coronary physiology.
  • Inflammatory markers are increasingly recognized as contributors to cardiovascular disease pathogenesis.

Purpose of the Study:

  • To investigate the association between key inflammatory parameters and quantitative flow ratio (QFR) in stable CAD patients.
  • To determine if neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII) correlate with impaired coronary flow.

Main Methods:

  • Cross-sectional study of 450 stable CAD patients.
  • Logistic regression analysis to assess associations between inflammatory markers (NLR, PLR, MLR, SII) and QFR ≤0.80.
  • Inflammatory markers evaluated as both continuous and binary variables.

Main Results:

  • Monocyte-to-lymphocyte ratio (MLR) and systemic immune-inflammation index (SII) were significantly associated with a QFR ≤0.80, indicating reduced coronary flow.
  • Neutrophil-to-lymphocyte ratio (NLR) showed borderline significance.
  • Platelet-to-lymphocyte ratio (PLR) was not significantly associated with QFR.

Conclusions:

  • MLR and SII are significant indicators of impaired coronary physiology in stable CAD.
  • These inflammatory indices may serve as valuable biomarkers for evaluating coronary artery disease severity.